Author: Steve Kopczak

• Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
• Tanya Gupta T, Vinayak S, Telli M.
• Breast Cancer Res Treat. 2022 Nov 1. doi: 10.1007/s10549-022-06780-4. Epub ahead of print.

• Source abstract

• Review

• Concurrent Pathogenic Variants of BRCA1, MUTYH and CHEK2 in a Hereditary Cancer Family.
• Agaoglu NB, Ng OH, Unal B, Dogan OA, Amanvermez U, Yildiz J, Doganay L, Ghazani A, Rana HQ.
• Cancer Genet. 2022 Nov 1. doi: 10.1016/j.cancergen.2022.10.144. Epub ahead of print.

• Source abstract

• Case report

• The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients.
• Baz M, Gondran-Teiller V, Bressac B, Cabaret O, Fievet A, Dimaria M, Goldbarg V, Colas C, Bonnet-Dupeyron MN, Tinat J, Lebrun M, Mari V, Limacher JM, Corsini C, Ginglinger E, Saurin JC, Brahimi A, Rouzier C, Giraud S, Schuster H, Hollebecque A, Boige V, Cauchin E, Malka D, Caron O, Rouleau E.
• Dig Dis Sci. 2022 Oct 31. doi: 10.1007/s10620-022-07733-z. Epub ahead of print.

• PMID: 36315333
• PubMed abstract
• Source abstract

• Germline and somatic variants in ovarian carcinoma: a next-generation sequencing (NGS) analysis.
• Andrikopoulou A, Zografos E, Apostolidou K, Kyriazoglou T, Papatheodoridi AM, Kaparelou M, Koutsoukos K, Liontos M, Dimopoulos M, Zagouri F.
• Front Oncol. 2022 Oct 31;12:1030786. doi: 10.3389/fonc.2022.1030786.

• Free Full Text

• BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling.
• Shaashua L, Ben-Shmuel A, Pevsner-Fischer M, Friedman G, Levi-Galibov O, Nandakumar S, Barki D, Nevo R, Brown LE, Zhang W, Stein Y, Lior C, Kim HS, Bojmar L, Jarnagin WR, Lecomte N, Mayer S, Stok R, Bishara H, Hamodi R, Levy-Lahad E, Golan T, Porco JA Jr, Iacobuzio-Donahue CA, Schultz N, Tuveson DA, Lyden D, Kelsen D, Scherz-Shouval R.
• Nat Commun. 2022 Oct 31;13(1):6513. doi: 10.1038/s41467-022-34081-3.

• PMID: 36316305
• PubMed abstract

• Free Full Text

• Hereditary variants of unknown significance in African American women with breast cancer.
• McDonald JT, Ricks-Santi LJ.
• PLoS One. 2022 Oct 31;17(10):e0273835. doi: 10.1371/journal.pone.0273835.

• PMID: 36315513
• PubMed abstract

• Free Full Text

• Metastatic involvement of inguinal lymph nodes as the first sign of endometroid carcinoma of the fallopian tube.
• Maradová E, Jánošík M, Pilka R, Marek R.
• Ceska Gynekol. 2022 Fall;87(5):328-332. English. doi: 10.48095/cccg2022328.

• PMID: 36316213
• PubMed abstract
• Source abstract

• Case report

• Somatic Inactivation of Breast Cancer Predisposition Genes in Tumours Associated with Pathogenic Germline Variants.
• Lim BWX, Li N, Mahale S, Mcinerny S, Zethoven M, Rowley SM, Huynh J, Wang T, Lee JEA, Friedman M, Devereux L, Scott RJ, Sloan EK, James PA, Campbell IG.
• J Natl Cancer Inst. 2022 Oct 31:djac196. doi: 10.1093/jnci/djac196. Epub ahead of print.

• PMID: 36315097
• PubMed abstract
• Source abstract

• Free Full Text (PDF)

• PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
• Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Piane CD, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S.
• Breast. 2022 Oct 29:S0960-9776(22)00179-5. doi: 10.1016/j.breast.2022.10.014. Epub ahead of print.

• Meta-Analysis
• Free Full Text

• Development of a web-based, theory-guided narrative intervention for women at elevated risk for breast cancer.
• Katz ML, Senter L, Reiter PL, Emerson B, Ennis AC, Shane-Carson KP, Aeilts A, Cassingham HR, Schnell PM, Agnese DM, Toland AE, Sweet K.
• Patient Educ Couns. 2022 Oct 29:S0738-3991(22)00820-5. doi: 10.1016/j.pec.2022.10.348. Epub ahead of print.

• Source abstract

• Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
• Negri S, De Ponti E, Sina FP, Sala E, Dell'Oro C, Roversi G, Lazzarin S, Delle Marchette M, Inzoli A, Toso C, Fumagalli S, Campanella M, Kotsopoulos J, Fruscio R.
• Mol Genet Genomic Med. 2022 Oct 28:e2071. doi: 10.1002/mgg3.2071. Epub ahead of print.

• PMID: 36307994
• PubMed abstract
• Source abstract

• Free Full Text

• PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?
• Loguidice CT.
• OncLive. 2022 Oct 28.

• Review
• Free Full Text

• Platinum-based chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): summary of evidence and application in clinical practice.
• Reinacher-Schick A, Arnold D, Venerito M, Goekkurt E, Kraeft AL, Seufferlein T.
• Oncol Res Treat. 2022 Oct 28. doi: 10.1159/000527692. Epub ahead of print.

• PMID: 36310006
• PubMed abstract
• Source abstract

• Review

• Adolescent Triple-negative Breast Cancer with Germline Pathogenic Variants in both BRCA1 and TP53 Genes: A Case Report.
• Chen D, Yuan M, Zhang Y, Zhang C, Wan D.
• Front Oncol. 2022 Oct 26;12:970641. doi: 10.3389/fonc.2022.970641.

• Case report
• Free Full Text

• PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.
• Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G.
• Int J Mol Sci. 2022 Oct 25;23(21):12876. doi: 10.3390/ijms232112876.

• Source abstract

• Free Full Text

• The DNA damage induced immune response: Implications for cancer therapy.
• Barros EM, McIntosh SA, Savage KI.
• DNA Repair (Amst). 2022 Oct 3;120:103409. doi: 10.1016/j.dnarep.2022.103409. Epub ahead of print.

• PMID: 36308822
• PubMed abstract

• Review
• Free Full Text